Direct Answer
264 SEC filers are classified under the Standard Industrial Classification codes that describe the rare disease biotechnology industry, and their latest annual reports show $546.7 billion of combined revenue and a median operating margin of -320.5%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Rare disease biotechnology companies develop drugs for conditions affecting small patient groups, often with orphan designation benefits. Prices are high, populations are small, and each product depends on diagnosis and patient identification. The first numbers to compare across companies here are patients on therapy and net price, pipeline stage and cash runway.
Key Industry Metrics
- Patients on therapy and net price: Number of patients treated and price received after discounts. Small populations mean few patients generate large revenue, so both matter.
- Pipeline stage: Where candidates sit in development. Late-stage candidates are nearer to launch, and orphan status often speeds review.
- Cash runway: Months of spending covered by cash on hand. Without sales, runway sets how long programs can continue.
- Orphan exclusivity timeline: Dates when special market protection for rare disease drugs ends. It shows how long competitors are blocked.
- Diagnosis rate: Share of affected patients who are identified and diagnosed. Low rates limit growth, so better testing can expand treated patients.
Primary Macro Drivers
- Regulatory approvals with orphan incentives: Orphan designation brings tax credits, fee waivers and market exclusivity, which lengthens protection and lowers cost of development.
- Payer coverage: Insurers decide whether to pay for very costly drugs, so coverage affects patients on therapy and net price.
- Genetic testing and diagnosis: Better genetic testing finds patients earlier and more completely, which grows patients on therapy and eligible populations.
- Clinical data: Strong data in a small group can be enough for approval, so trial results set approval and pricing outcomes.
Major Risks
- Small markets: A small patient count limits sales per product, so a company needs high prices or several products; watch patients on therapy and net price.
- Pricing scrutiny: Very high prices attract attention from payers and legislators, which can lead to negotiation or limits; watch policy proposals and payer comments.
- Trial failure: A failed or delayed study can remove the main source of future revenue; watch pipeline stage and readout timing.
- Single-product dependence: One product often accounts for most revenue, so a safety issue or rival launch moves results; watch revenue by product.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Rare Disease Biotechnology Filers in the SEC Record
264 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification codes 2836, 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $546.7 billion of revenue. Median revenue growth over the prior year was 11.6%. Median operating margin was -320.5% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 57 of 264 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Amgen Inc | $36.8 billion | 10.0% | 24.7% | 21.0% | FY 2025 |
| Gilead Sciences, Inc. | $29.4 billion | 2.4% | 34.0% | 28.9% | FY 2025 |
The 8 largest of 264 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Rare Disease Biotechnology guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Rare Disease Pharmaceuticals
- Proteomics
- Regenerative Medicine
- Prosthetics
- Remote Patient Monitoring
- Primary Care Platforms
- Research & Manufacturing Services
- Physician Practice Management
Put it to work
Frequently Asked Questions
What are the main KPIs for the Rare Disease Biotechnology industry?
Key performance indicators for the Rare Disease Biotechnology industry include: Patients on therapy and net price, Pipeline stage, Cash runway, Orphan exclusivity timeline, Diagnosis rate. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Rare Disease Biotechnology industry?
The Rare Disease Biotechnology industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Rare Disease Biotechnology industry?
The primary risks for Rare Disease Biotechnology companies include: Small markets, Pricing scrutiny, Trial failure, Single-product dependence. Investors should assess each company's exposure to these factors and its track record of navigating them.